Brind.

EMA granted Orphan Drug Designation to KRRO-110, a drug candidate from Korro Bio, Inc.

2 reports, 1 independent Updated Aug 12
Gone quiet
Reports
2
Developments
1
Repetition
50%

New informationRepeats or wire copies

AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.

What happened

Some supportReported by 1 outlet

EMA granted Orphan Drug Designation to KRRO-110, a drug candidate from Korro Bio, Inc.

Who's involved

What this event is mainly about
EMA

Keep exploring

The entities involved

  • EMA

    Japanese vocalist of the group DUSTCELL

    Nothing else this week.

Coverage

Newest first; wire copies grouped
  • GlobeNewswireKorro Reports Second Quarter 2025 Financial Results and Provides Business Updates — Interim readout from Phase 1/2a REWRITE clinical trial of KRRO-110 on track for the second half of 2025 — Completed
  • GlobeNewswireKorro Receives European Medicines Agency Orphan Drug Designation for KRRO-110 CAMBRIDGE, Mass., July 21, 2025 (GLOBE NEWSWIRE) -- Korro Bio, Inc. (Korro) (Nasdaq: KRRO), a clinical-stage biopharmaceu